Medical care informed by genomic information is beginning to move into clinical practice. The Electronic Medical Records and Genomics (eMERGE) network through its initial phases has provided much of the groundwork for this transformation. The Geisinger Health System project, EMR-Linked Biobank for Translational Genomics intends to build on the knowledge and experience from eMERGE phase II to accelerate discovery and implementation while expanding our understanding of the sociocultural implications of genomics in medicine. We will accomplish this goal through three specific aims: 1) Use existing biospecimens, genotype and sequence data and EMR-generated phenotypes for discovery in the proposed disorders: familial hypercholesterolemia and chronic rhinosinusitis, 2) Develop and test approaches for implementation of genomic information in clinical practice, 3) Explore, develop and implement novel approaches for family-centered communication around clinically relevant genomic results. We currently have over 60,000 patients broadly consented for research with a large and increasing proportion consented for return of results and deposition in the electronic health record. Over 18,000 patients are genotyped on high density platforms. Our two proposed phenotypes, familial hypercholesterolemia (FH) and chronic rhinosinusitis (CRS) were chosen because both conditions have a significant public health impact in the United States, but they are also ideally suited to the specific aims of the project. They provide opportunities for innovation and extension of current eMERGE methods. While many of these innovations will take advantage of the sequencing done as part of the project, there are several other areas emphasized in the funding opportunity that will broaden the scope of eMERGE research. One of the areas of emphasis for eMERGE III is exploring the familial return of actionable results. FH is well suited to this, as the current clinical recommendation is cascade testing of family members for all diagnosed patients. Currently this relies on the patient to contact at risk family members, but this is less than optimal. We will explore this issue using qualitative and quantitative methods and use the results to design and test novel family communication strategies. Gene-environment interactions play an important role in the development and severity of disease. These are very difficult to study. We propose novel approaches that leverage the assets of Geisinger Health System and the eMERGE Network to develop and apply methods to extend existing projects that study the impact of environment on CRS. This would include the first large scale environment-wide association studies (EWAS). Finally, we propose to lead efforts to apply the tools of economic modeling and analysis to eMERGE projects to begin to quantify the value of implementation of genomic medicine in the US healthcare system. These proposed innovations will magnify the already significant impact that the eMERGE program has had in moving genomic medicine from a dream to a reality.

Public Health Relevance

Through this application GHS seeks to continue its participation in the eMERGE Network for Phase III - Study Investigators U01 (RFA-HG-14-025) funding opportunity. We propose 3 specific aims: 1) use existing biospecimens, genotype and sequence data and EMR-generated phenotypes for discovery and validation of gene-phenotype associations; 2) develop and test approaches for implementation of genomic information in clinical practice; develop and implement novel approaches for family-centered communication around clinically relevant genomic results

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01HG008679-02S1
Application #
9248725
Study Section
Special Emphasis Panel (ZHG1-HGR-N (M1))
Program Officer
Li, Rongling
Project Start
2015-09-01
Project End
2019-05-31
Budget Start
2016-09-28
Budget End
2017-05-31
Support Year
2
Fiscal Year
2016
Total Cost
$98,294
Indirect Cost
$38,722
Name
Geisinger Clinic
Department
Type
DUNS #
079161360
City
Danville
State
PA
Country
United States
Zip Code
17822
Verma, Anurag; Bradford, Yuki; Dudek, Scott et al. (2018) A simulation study investigating power estimates in phenome-wide association studies. BMC Bioinformatics 19:120
Basile, Anna O; Byrska-Bishop, Marta; Wallace, John et al. (2018) Novel features and enhancements in BioBin, a tool for the biologically inspired binning and association analysis of rare variants. Bioinformatics 34:527-529
Fossey, Robyn; Kochan, David; Winkler, Erin et al. (2018) Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience. J Pers Med 8:
Verma, Shefali Setia; Josyula, Navya; Verma, Anurag et al. (2018) Rare variants in drug target genes contributing to complex diseases, phenome-wide. Sci Rep 8:4624
Pet, Douglas B; Holm, Ingrid A; Williams, Janet L et al. (2018) Physicians' perspectives on receiving unsolicited genomic results. Genet Med :
Jones, Laney K; Kulchak Rahm, Alanna; Gionfriddo, Michael R et al. (2018) Developing Pharmacogenomic Reports: Insights from Patients and Clinicians. Clin Transl Sci 11:289-295
Wei, Wei-Qi; Li, Xiaohui; Feng, Qiping et al. (2018) LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. Circulation 138:1839-1849
Kulchak Rahm, Alanna; Bailey, Lindsay; Fultz, Kara et al. (2018) Parental attitudes and expectations towards receiving genomic test results in healthy children. Transl Behav Med 8:44-53
Wang, Liuyang; Pittman, Kelly J; Barker, Jeffrey R et al. (2018) An Atlas of Genetic Variation Linking Pathogen-Induced Cellular Traits to Human Disease. Cell Host Microbe 24:308-323.e6
Beaulieu-Jones, Brett K; Lavage, Daniel R; Snyder, John W et al. (2018) Characterizing and Managing Missing Structured Data in Electronic Health Records: Data Analysis. JMIR Med Inform 6:e11

Showing the most recent 10 out of 19 publications